Evropska unija - bolgarščina - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - Ваксини - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

dynavax gmbh - повърхностен антиген на хепатит В - Хепатит Б - Ваксини - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - Ваксини - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - Антихеморагични - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - Ваксини - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - Инфекции на респираторния синцитиален вирус - Ваксини - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - Инфекции на респираторния синцитиален вирус - Ваксини - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. Вижте раздели 4. 2 и 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - Прекурсорна клетъчна лимфобластна левкемия-лимфом - Антинеопластични средства - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Evropska unija - bolgarščina - EMA (European Medicines Agency)

sanofi b.v. - агалсидаза бета - Фабри болест - Други стомашно-чревния тракт и обмяната на веществата средства, - fabrazyme е показан за дългосрочна ензимна заместителна терапия при пациенти с потвърдена диагноза на болестта на fabry (дефицит на α-галактозидаза-А).